A week ago we closed our note on Sephora at M&S and the Boots talks with two questions about Boots: whether the agreement would be signed this month at the price reported, and whether the Westons would say anything about beauty in their first statement. The first answer arrived within a day. The second is in what the statement leaves out.
Signed, at the number reported
On Wednesday, October 7, Wittington Investments, the holding company of the Canadian branch of the Weston family, signed a definitive agreement to buy Boots from Sycamore Partners and the Pessina family for 8.9 billion dollars including assumed debt, as reported by The Grocer. City AM puts that at 6.7 billion pounds. The reports of October 1 had it at close to 9 billion dollars. Whatever the Westons won by lowering their offer over the summer, the last week of talks did not move the figure.
The perimeter is the part a beauty reader should look at. Wittington is buying the UK and Ireland retail operations, Boots Opticians, the Thailand and franchised businesses, and the No7 Beauty Company, as reported by The Grocer. Sycamore and Stefano Pessina's family keep Farmacias Benavides in Mexico and Alliance Healthcare Deutschland. No7 could have been carved out and sold as a brand company. It was not. The buyer wanted the retailer and its own label together.
Closing is expected in the first quarter of 2027, subject to regulatory approvals, as reported by Personal Care Insights. Galen Weston, chairman of Wittington, becomes chairman of Boots at that point. The chief executive stays: Alex Baldock, formerly of Currys, who started in September, as reported by The Grocer.
Half the equity belongs to an insurer
The line that most headlines skipped is in Fairfax Financial's own statement. The Toronto holding company has committed "up to approximately US$2.3 billion for the purposes of satisfying the purchase price," and after closing "it is expected that Fairfax will own 50% of the equity of Boots, with Wittington having operational control," as quoted by Insurance Journal.
So this is a Weston deal in governance and a shared one in capital. That matters for how to read Galen Weston's central phrase, that the family sees "a meaningful opportunity to make a great business even better through stable long-term ownership," as quoted by City AM. Stable, compared with what came before, is a fair claim: Boots has changed hands twice in little over a year, and the agreement ends the speculation about a return to the London Stock Exchange, as City AM notes. But half the equity sits with a financial partner whose business is returns on capital, and the sellers were private equity. Patient ownership is the promise. It is not yet the record.
What the statement says, and what it does not
Wittington says it will invest in "upgrading stores, optimizing the online experience and supporting the expansion of healthcare services," as quoted by Insurance Journal. In the passages of the announcement relayed by the trade and business press we read, those are the three priorities. Beauty is not named as one.
That is a curious silence. Boots carries more than 500 beauty brands, as reported by Premium Beauty News, and added 61 in its last fiscal year, Fenty Beauty and MAC among them, as reported by Personal Care Insights, which credits the modernized beauty division with helping lift results. Those results were revenue of 7.5 billion pounds, up 3.2%, and pre-tax profit of 337 million pounds, up about 25%, in the year to August 2025, as the same outlet reports. Beauty is where the brand list got longer and where the store got its newness. It is also where the competition is now arriving through other people's doors, with Sephora due inside 100 M&S stores from spring 2027.
There are two ways to read the omission. The generous one is that "upgrading stores" means beauty halls, and nobody thought it needed saying. The less generous one is that the investment case is a pharmacy and healthcare case, and beauty is assumed to look after itself. We lean toward the first, for a reason that has nothing to do with the press release: the Westons already control, through George Weston Limited and Loblaw, more than 1,300 Shoppers Drug Mart pharmacies in Canada, as reported by Retail Insider, and that chain is the best working example of a drugstore that built a prestige beauty business inside itself. A family that has run that format for a decade does not need telling what the front of a pharmacy is for. But a statement is a list of what an owner chose to promise, and beauty is not on it.
The Canadian shortcut that nobody announced
The obvious industrial idea is to connect the two beauty operations. No7 is already sold at Shoppers Drug Mart, some of it marketed as exclusive to the chain, as reported by Retail Insider. Shoppers has prestige relationships and a format Boots could study. On paper the Westons now control both ends.
On paper only. The buyer is Wittington, not Loblaw. Loblaw is not part of the transaction, no change to No7's Canadian distribution has been announced, and nothing indicates a plan to combine the Boots and Shoppers beauty businesses, as Retail Insider reports. Two companies with a common controlling family are not one buying office, and a listed Canadian grocer has its own shareholders to answer to. The synergy is real as knowledge. As structure it does not exist yet, and brands should not negotiate as if it did.
Cheap, if the estate gets fixed
Carl Boutet, a retail strategist quoted by Retail Insider, offered the sharpest comparison of the week: "In real terms, the Westons are paying roughly a quarter less for Boots than they paid for Shoppers." Loblaw's purchase of Shoppers was announced in 2013 at around 12.4 billion Canadian dollars. Retail Insider itself warns the comparison is inexact, given the different currencies and the assumed debt. Boutet supplies the caveat that counts: "Is that a bargain? Only if they fix the estate and the economics of community pharmacy."
That is the right frame. Boots is more than 1,800 stores and over 50,000 people, with 17 consecutive quarters of comparable sales growth behind it by August 2025, as reported by Retail Insider. It is not a turnaround. It is a large, old estate with uneven stores, a pharmacy model under funding pressure and a beauty counter that is suddenly contested. The price reflects all three.
What to watch
Whether the approvals arrive on the first-quarter timetable. Whether Wittington or Mr. Baldock puts a number on store investment, and how much of it is beauty space. Whether anything moves between No7 and Shoppers, in either direction, once the deal closes. And which of Boots' prestige brands sign for Sephora at M&S before the new owner has the keys. We will come back to it at closing.
Sources: The Grocer, "Boots owner agrees $9bn sale to Weston family", October 2026; City AM, "Billionaire Weston family buys Boots for $9bn", October 2026; Insurance Journal, "Canada's Weston Family and Fairfax Financial Partner to Buy UK's Boots in $8.9B Deal", October 8, 2026 (quoting Fairfax Financial's statement); Personal Care Insights, "Boots sold to Weston family's Wittington Investments for US$8.9B", October 7, 2026; Retail Insider, "Weston Family's Wittington to Acquire Boots in US$8.9-Billion Deal", October 2026; Premium Beauty News, "Boots sold to Canada's Wittington", October 7, 2026; Cosmetics Business, report on the sale of Boots to Wittington Investments, October 7, 2026.
